Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives
出版年份 2020 全文链接
标题
Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives
作者
关键词
-
出版物
DRUGS
Volume 80, Issue 12, Pages 1203-1210
出版商
Springer Science and Business Media LLC
发表日期
2020-07-15
DOI
10.1007/s40265-020-01361-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2020) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular therapies for HCC: Looking outside the box
- (2020) Sandrine Faivre et al. JOURNAL OF HEPATOLOGY
- Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD‐L1 Expression
- (2020) Xiaobo Yang et al. ONCOLOGIST
- Cabozantinib in advanced hepatocellular carcinoma: Efficacy and safety data from an international multicenter real-world cohort.
- (2020) Fabian Finkelmeier et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial.
- (2019) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma
- (2019) Lorenza Rimassa et al. CANCER TREATMENT REVIEWS
- Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.
- (2019) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- O-022Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
- (2019) R Miksad et al. ANNALS OF ONCOLOGY
- Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma
- (2018) Mohamed Bouattour et al. HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
- (2018) Lorenza Rimassa et al. LANCET ONCOLOGY
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours
- (2017) Patrick Schöffski et al. EUROPEAN JOURNAL OF CANCER
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma
- (2017) Manuela Schmidinger et al. ONCOLOGIST
- Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells
- (2016) Zeynep Firtina Karagonlar et al. CANCER SCIENCE
- Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
- (2016) Riccardo Lencioni et al. JOURNAL OF HEPATOLOGY
- Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib
- (2016) Lorenza Rimassa et al. Oncotarget
- Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
- (2015) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects
- (2015) Linh Nguyen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
- (2015) Jordi Bruix et al. LANCET ONCOLOGY
- Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
- (2015) L Zhou et al. ONCOGENE
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Health-Related Quality of Life in Patients With Hepatocellular Carcinoma: A Systematic Review
- (2010) Sheng–Yu Fan et al. Clinical Gastroenterology and Hepatology
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?
- (2010) C. Vaklavas et al. ONCOLOGIST
- Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib
- (2008) M. E. Lacouture et al. ANNALS OF ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now